drugset / Trial / NCT01779570

Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections

NCT01779570

Phase 4 Completed 68 enrolled Chinese University of Hong Kong
RandomizedParallel-groupOpen-labelTreatment

Summary

Influenza lower respiratory tract infection (LRTI) is a major cause of morbidity and mortality worldwide. While viral replication can be suppressed by antiviral treatment, excessive inflammatory responses, which are increasingly recognized to contribute to severe influenza complications, remain unopposed. Macrolides have been used widely to treat community-acquired pneumonia, and shown to exert anti-inflammatory effects in other respiratory diseases, providing clinical benefits. In this randomized, open-label, multicenter study, we aim to investigate the anti-inflammatory effects of macrolide treatment in influenza LRTI. Its impacts on the cytokine response, viral clearance, symptoms and disease resolution will be studied. Such results may lead to the development of new therapeutic approaches against severe influenza infection, and provide better insights into disease pathogenesis.

Timeline

Start
2013-02
Primary completion
2016-04
Completion
2016-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 500 mg Oral

Indications